Cardiovascular trials

An inadequate supply of oxygen to the heart, due to narrowed coronary arteries, may result in impaired contractile performance during exercise. The use of glucose rather than fat as the major energy source may enable the heart to continue pumping…

COPD is the fourth leading cause of death globally and the only major cause that is predicted to increase in the coming decades. Although COPD is initially a pulmonary disease (traditionally caused by cigarette smoke, but increasingly by biomass…

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death globally and the only major cause that is predicted to increase in the coming decades. Although COPD is initially a pulmonary disease (traditionally caused by…

Acute coronary syndromes (ACS) result from coronary plaque(s) disruption, which initiates a thrombotic process leading to partial or complete obstruction of the vessel lumen with subsequent myocardial ischaemia and necrosis. The mainstay of…

This is a pilot proposal to understand the changes in physiology in patients undergoing scheduled therapy with Darbepoetin as part of their normal NHS care. It is therefore an observational pilot study of changes in physiology before and after…

The TACTIC-E clinical trial is testing whether novel therapeutic agents or novel combinations of approved agents can prevent the development of severe symptoms in patients hospitalised with strongly suspected or confirmed COVID-19. By targeting…

The TACTIC-R trial, using licenced drug "Repurposed" for treatment of COVID-19-related disease, launched in Cambridge on 7th May 2020. The trial has three arms in parallel-group, randomised design. 

The treatments currently being…